Armenia - Kiingereza - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmathen s.a. - risedronic acid (risedronate sodium) - tablets film-coated - 35mg

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

abacus medicine a.s. - risedronic acid 32,5 mg - eq. sodium risedronate 35 mg - film-coated tablet - risedronic acid

Marekani - Kiingereza - NLM (National Library of Medicine)

actavis pharma, inc. - risedronate sodium hemi-pentahydrate (unii: hu2yaq274o) (risedronic acid - unii:km2z91756z), risedronate sodium monohydrate (unii: f67l43ut5c) (risedronic acid - unii:km2z91756z) - risedronate sodium anhydrous 30.1 mg - risedronate sodium is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ].  the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risedronate sodium is contraindicated in patients with the following conditions: - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see warnings and precautions (5.2) ] -

Marekani - Kiingereza - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium 5 mg - risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, risedronate reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1, 14.2) ]. risedronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis. risedronate sodium tablets are indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d. risedronate sodium tablets are indicated for treatment of paget’s disease of bone in men and women. the optimal duration of use has not been determined. the safety and effectiveness of risedronate

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

warner chilcott uk limited - risedronate sodium ; calcium carbonate; colecalciferol - granules effervescent - 35 + 1000/880 iu milligram - risedronic acid, calcium and colecalciferol, sequential

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

warner chilcott uk limited - risedronate sodium ; calcium carbonate ; colecalciferol concentrate (oily form) [vitamin d3] - granules effervescent - 35 & 1000/880 iu milligram - risedronic acid, calcium and colecalciferol, sequential

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - calcium ; risedronate sodium - film coated tablet - 35/500 milligram - risedronic acid and calcium, sequential

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - risedronate sodium - film-coated tablet - 35 milligram(s) - risedronic acid

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - risedronate sodium - film coated tablet - 35 milligram - risedronic acid

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - risedronate sodium; calcium carbonate; colecalciferol - effervescent granules + film-coated tablet - 35 mg + 1000 mg/800 international unit(s) - risedronic acid, calcium and colecalciferol, sequential